local_hospital

SPECJALISTYCZNA PORADNIA KARDIOLOGICZNA I NADCISNIENIA TETNICZEGO prof. Beata Wozakowska-Kaplon

Address
lock Available on a paid plan

Specialist Cardiology and Hypertension Center

Under the leadership of Prof. Beata Wozakowska-Kaplon, this specialized center focuses on advanced cardiovascular research with particular expertise in hypertension management and acute coronary syndromes. The facility conducts sophisticated clinical investigations aimed at optimizing treatment strategies for patients with complex cardiovascular conditions.

  • Difficult-to-treat and resistant hypertension management using ambulatory blood pressure monitoring
  • Acute coronary syndrome and secondary cardiovascular event prevention
  • Novel anticoagulation and cardiovascular protection therapies

The center demonstrates significant experience in managing uncontrolled hypertension through systematic evaluation of triple combination therapies and specialized interventions. Research initiatives include comprehensive assessment of single-pill combinations and advanced pharmacological strategies including mineralocorticoid receptor antagonists. The facility also participates in large-scale international cardiovascular trials evaluating innovative approaches to reducing major adverse cardiovascular events following myocardial infarction, contributing to evidence-based advancement in secondary prevention strategies.

Site Overview

assignment
3
connected trials
corporate_fare
4
sponsors
science
15
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
3
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
4
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
3
Outperforms 56% of sites
public
Therapeutic diversity
2areas
Outperforms 53% of sites
groups
Sponsor diversity
4sponsors
Outperforms 66% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in SPECJALISTYCZNA PORADNIA KARDIOLOGICZNA I NADCISNIENIA TETNICZEGO prof. Beata Wozakowska-Kaplon

lock Showing 1 of 3 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary SyndromeJanssen Cilag InternationalPhase IIINot RecruitingNov 2023Jan 2026

IMP list

lock Showing 1 of 15 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Acetylsalicylic Acid1Unknown2023-11-212023-11-21

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.